<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1868">
  <stage>Registered</stage>
  <submitdate>5/03/2008</submitdate>
  <approvaldate>5/03/2008</approvaldate>
  <nctid>NCT00633880</nctid>
  <trial_identification>
    <studytitle>Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)</studytitle>
    <scientifictitle>Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH</scientifictitle>
    <utrn />
    <trialacronym>NOH302</trialacronym>
    <secondaryid>Droxidopa NOH302</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Symptomatic Neurogenic Orthostatic Hypotension (NOH)</healthcondition>
    <healthcondition>Non-diabetic Neuropathy</healthcondition>
    <healthcondition>Primary Autonomic Failure</healthcondition>
    <healthcondition>Dopamine Beta Hydroxylase Deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - Droxidopa

Experimental: Droxidopa - Double-blind

Placebo Comparator: Placebo - Double-blind


Treatment: drugs: Placebo
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Treatment: drugs: Droxidopa
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) - OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Fatigue (OHSA Item 4) - OHSA item 4 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Weakness (OHSA Item 3) - OHSA item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Vision (OHSA Item 2) - OHSA item 2 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Concentration (OHSA Item 5) - OHSA item 5 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Head/Neck Discomfort (OHSA Item 6) - OHSA item 6 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score) - The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite) - The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6) - OHSA composite scale (items 2-6) is the average of five OHSA items: 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing; - Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>PATIENT INCLUSION CRITERIA:

          -  Male or female and aged 18 years or over;

          -  Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic
             Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic
             Autonomic Neuropathies;

          -  A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic
             blood pressure of at least 10 mmHg, within 3 minutes after standing;

          -  Provide written informed consent to participate in the study and understand that they
             may withdraw their consent at any time without prejudice to their future medical care.

        MAIN PATIENT EXCLUSION CRITERIA:

          -  Taking ephedrine or midodrine; Patients taking ephedrine or midodrine may enroll after
             a minimum 7 day washout period;

          -  Taking anti-hypertensive medication;

          -  Have a history of more than moderate alcohol consumption;

          -  Women who are pregnant or lactating;

          -  Have a history of closed angle glaucoma;

          -  Have pre-existing sustained severe hypertension (BP &gt; 180/110 mmHg in the sitting
             position);

          -  Have atrial fibrillation or, in the investigator's opinion, have any other significant
             cardiac arrhythmia;

          -  In the investigator's opinion, have any other significant systemic, hepatic, cardiac
             or renal illness;

          -  Have diabetes mellitus or insipidus;

          -  Have a known or suspected malignancy;

          -  Have known gastrointestinal illness or other gastrointestinal disorder that may, in
             the investigator's opinion, affect the absorption of study drug;

          -  In the investigator's opinion, have clinically significant abnormalities on clinical
             examination or laboratory testing;

          -  Have a serum creatinine level &gt; 130 Âµmol/L;</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>181</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Baker Heart Research Institute - Melbourne</hospital>
    <hospital>Austin Hospital - Heidelburg</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3084 - Heidelburg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Private Bag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Chelsea Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Chiltern International Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to see whether droxidopa is effective in treating symptoms of
      neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic
      Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta
      Hydroxylase deficiency.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00633880</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Horacio Kaufmann, MD</name>
      <address>New York University School of Medicine</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>